Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Coronavirus Infection - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Coronavirus Infection - Pipeline Review, H1 2015', provides an overview of the Coronavirus Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Coronavirus Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Coronavirus Infection Overview 7 Therapeutics Development 8 Pipeline Products for Coronavirus Infection - Overview 8 Pipeline Products for Coronavirus Infection - Comparative Analysis 9 Coronavirus Infection - Therapeutics under Development by Companies 10 Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 11 Coronavirus Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Coronavirus Infection - Products under Development by Companies 15 Coronavirus Infection - Products under Investigation by Universities/Institutes 16 Coronavirus Infection - Companies Involved in Therapeutics Development 17 AstraZeneca PLC 17 Hemispherx Biopharma, Inc. 18 Humabs BioMed SA 19 Inovio Pharmaceuticals, Inc. 20 NanoViricides, Inc. 21 Novavax, Inc. 22 Coronavirus Infection - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 Cell Therapy for Coronavirus Infection - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 coronavirus vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 EMER-IT - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 interferon alfa-n3 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 interferon beta-1a - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 MERS-COV - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 MERS-CoV Vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 middle east respiratory syndrome coronavirus vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Monoclonal Antibody for Coronavirus Infection - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Monoclonal Antibody for MERS and SARS - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule to Inhibit Viral Protease for Viral Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Vaccine for Respiratory and Infectious Diseases - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Coronavirus Infection - Recent Pipeline Updates 45 Coronavirus Infection - Dormant Projects 49 Coronavirus Infection - Product Development Milestones 50 Featured News & Press Releases 50 Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Number of Products under Development for Coronavirus Infection, H1 2015 8 Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Comparative Analysis by Unknown Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Coronavirus Infection - Pipeline by AstraZeneca PLC, H1 2015 17 Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H1 2015 18 Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2015 19 Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 20 Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2015 21 Coronavirus Infection - Pipeline by Novavax, Inc., H1 2015 22 Assessment by Monotherapy Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2015 45 Coronavirus Infection - Dormant Projects, H1 2015 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
